Fig. 4From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker programKaplan-Meier curves for progression-free survival depending on sVEGFR2 at baseline dichotomized at the median 4688 pg/ml. Hazard ratio 2.557, 95 % CI 1.248–5.237, P = 0.010Back to article page